JDRF Welcomes Novo Nordisk as Official National Sponsor of the Ride to Cure Diabetes
NEW YORK, April 4, 2013 /PRNewswire-USNewswire/ — JDRF is pleased to announce that Novo Nordisk, a global healthcare company with 90 years of innovation and leadership in diabetes care, has become the official national presenting sponsor of the JDRF Ride to Cure Diabetes. The annual, nationwide fundraising event brings together cyclists of all levels from around the world to raise much needed funds toward type 1 diabetes (T1D) research and participate in a destination cycling experience. Novo Nordisk has consistently been one of the largest corporate teams to participate in the Ride for more than eight years, with many of its staff, including its CEO Lars Rebien Sorensen, taking part to raise critical funds toward lessening the burden of T1D on the road to cure the disease.
“The Novo Nordisk team has been a source of great support through the Ride to Cure Diabetes for nearly a decade, and JDRF is grateful for this next level of partnership with a company that shares our goal of lifting the burden of type 1 diabetes,” said Jeffrey Brewer, president and CEO of JDRF.
Novo Nordisk’s sponsorship is a two-year commitment of $1 million, beginning with the FY2014 Ride series. For more information on how you can join Novo Nordisk and JDRF on our ride to cure T1D click here .
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.
As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. More than 80 percent of JDRF’s expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization’s efficiency and effectiveness.
For more information, please visit jdrf.org.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com. For more information about our U.S. activities, follow us on Twitter at @NovoNordiskUS.